WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s FARXIGA ® (dapagliflozin) has been approved by the US Food and Drug Administration (FDA) to improve glycemic control in pediatric patients with type-2 ...
Treatment with dapagliflozin led to a statistically significant improvement in HbA1c compared with placebo. The Food and Drug Administration (FDA) has expanded the approval of Farxiga ® (dapagliflozin ...
Results from the DELIVER and DAPA-HF Phase III trials demonstrate FARXIGA’s efficacy in heart failure regardless of ejection fraction WILMINGTON, Del.--(BUSINESS WIRE)-- High-level results from the ...
Min Son of Hanol IP & Law finds encouragement for developers of new chemical entity drugs after the rulings handed down in a battle between AstraZeneca and several generic pharmaceutical companies In ...
Just over a year since AstraZeneca announced topline results, the FDA has approved a label expansion to include reducing cardiovascular (CV) death and heart failure–related hospitalizations for ...
(RTTNews) - AstraZeneca (AZN.L, AZN), on Monday, announced that its Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in China to reduce the risk of ...
WILMINGTON, Del.--(BUSINESS WIRE)--Today, new results from a pre-specified, patient level, pooled analysis from the Phase III DAPA-HF and DELIVER trials demonstrated mortality benefit of FARXIGA ® ...
Credit: Shutterstock. Dapagliflozin is sodium-glucose cotransporter 2 inhibitor. The Food and Drug Administration (FDA) has approved Farxiga (dapagliflozin) to reduce the risk of cardiovascular death ...
The European Commission (EC) approved AstraZeneca (NASDAQ:AZN) Forxiga for expanded use to treat heart failure (HF) with reduced ejection fraction (HFrEF) to cover patients across the full spectrum of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results